Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01284556 · ClinicalTrials.gov registry record · Phase 3
Evaluation Phenobarbital as Adjunctive Therapy in Participants With Partial Onset Seizures
A Phase 3 study, sponsored by West-Ward Pharmaceutical.
- Completed
- Registry status
- Phase 3
- Development phase
- 314
- Enrollment target
NCT01284556 is a Phase 3 study that has completed, run by West-Ward Pharmaceutical. The registered enrollment target is 314 participants.
The verdict
NCT01284556, a Phase 3 study, has completed, sponsored by West-Ward Pharmaceutical.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 314 participants
- Enrollment target
Study Summary
Primary: \- to evaluate the efficacy of phenobarbital in reducing seizure frequency. Secondary: * to confirm dose response relationship, * to assess the effects on Type I seizures, * to assess the safety of phenobarbital * to assess the drug tolerability.
Interventions
- DRUG Placebo tablet
- DRUG Phenobarbital
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 314 participants |
| Start Date | 2010-11 |
| Est. Completion | 2016-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01284556
The ClinicalTrials.gov registry entry for NCT01284556 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 314 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is West-Ward Pharmaceutical, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo tablet is the first listed.
NCT01284556 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01284556 about?
NCT01284556 is a clinical study titled "Evaluation Phenobarbital as Adjunctive Therapy in Participants With Partial Onset Seizures". Primary: \- to evaluate the efficacy of phenobarbital in reducing seizure frequency. Secondary: * to confirm dose response relationship, * to assess the effects on Type I seizures, * to assess the safety of phenobarbital * to assess the drug tolerability.
What is the current status of trial NCT01284556?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 314 participants. The study started on 2010-11. Estimated completion is 2016-04.
What interventions are being tested in trial NCT01284556?
The interventions under investigation include: Placebo tablet (DRUG), Phenobarbital (DRUG).
Who is sponsoring clinical trial NCT01284556?
This trial is sponsored by West-Ward Pharmaceutical, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.